These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18832933)

  • 1. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma.
    Solheim BG; Chetty R; Flesland O
    Curr Opin Hematol; 2008 Nov; 15(6):612-7. PubMed ID: 18832933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?
    Hellstern P
    Transfus Apher Sci; 2008 Aug; 39(1):69-74. PubMed ID: 18583192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection.
    Solheim BG
    Clin Med Res; 2006 Sep; 4(3):209-17. PubMed ID: 16988101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection.
    Solheim BG; Granov DA; Juravlev VA; Krawczyk M; Kubishkin VA; Patutko UI; Raab R
    Vox Sang; 2005 Jul; 89(1):19-26. PubMed ID: 15938736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma.
    Shanwell A; Andersson TM; Rostgaard K; Edgren G; Hjalgrim H; Norda R; Melbye M; Nyrén O; Reilly M
    Vox Sang; 2009 May; 96(4):316-23. PubMed ID: 19254234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas).
    Sinnott P; Bodger S; Gupta A; Brophy M
    Eur J Immunogenet; 2004 Dec; 31(6):271-4. PubMed ID: 15548265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate].
    Spannagl M; Joch Ch; Heindl B
    Hamostaseologie; 2006 Aug; 26(3 Suppl 1):S36-40. PubMed ID: 16953291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and side effects of therapy with plasma and plasma fractions.
    MacLennan S; Barbara JA
    Best Pract Res Clin Haematol; 2006; 19(1):169-89. PubMed ID: 16377549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply.
    AuBuchon JP; Birkmeyer JD
    JAMA; 1994 Oct; 272(15):1210-4. PubMed ID: 7933351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on preparation of universal plasma in Chinese Han population.
    Wang S; Zhou W; Zhuang Y; Zhang D; Li H; Wang D
    Transfus Apher Sci; 2012 Oct; 47(2):167-70. PubMed ID: 22874436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers.
    Jilma-Stohlawetz P; Kursten FW; Walasek C; Horvath M; Leitner G; List J; Quehenberger P; Schwameis M; Bartko J; Jilma B
    Transfusion; 2011 Jun; 51(6):1228-40. PubMed ID: 21332722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
    Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
    Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In search of plentiful universal donor plasma: what might Landsteiner say?
    Quillen K
    Transfusion; 2013 Aug; 53(8):1863-4. PubMed ID: 23927641
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pathogen inactivation in labile blood products: transfusion safety and economic impact].
    Cazenave JP
    Bull Acad Natl Med; 2006 Jan; 190(1):169-85; discussion 186-8. PubMed ID: 16878453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties.
    Noddeland H; Töllöfsrud S; Svennevig J; Bentsen G; Brosstad F; Solheim B
    Thromb Res; 2002 Oct; 107 Suppl 1():S33-7. PubMed ID: 12379291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood transfusion and blood-derived products transfusion. Immunologic principles and indications].
    Lamy B; Morel P; Hervé P
    Rev Prat; 1998 Mar; 48(5):549-53. PubMed ID: 9781121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.